Drug Profile


Alternative Names: Briciclib sodium; ON-013105; ON-014185

Latest Information Update: 15 Dec 2015

Price : $50

At a glance

  • Originator Temple University
  • Developer Onconova Therapeutics
  • Class Antineoplastics; Phenols; Phenyl ethers; Small molecules; Sulfones
  • Mechanism of Action Cyclin D1 inhibitors; Eukaryotic initiation factor 4E inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • No development reported Acute lymphoblastic leukaemia; Lymphoma

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Jun 2014 Phase-I clinical trials in Solid tumours (metastatic disease) in USA (IV) (NCT02168725)
  • 23 Sep 2011 Onconova completes enrolment in its phase I trial for Acute lymphoblastic leukaemia in USA (NCT01049113)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top